Lisa Herrinton, PhD

Lisa Herrinton, PhD Kaiser Permanente Division of Research
2000 Broadway
Oakland, CA 94612

(510) 891-3714 (phone)
lisa.herrinton@kp.org

Lisa Herrinton, PhD, is a senior research scientist at the Kaiser Permanente Northern California Division of Research and an associate editor with the American Journal of Epidemiology. Dr. Herrinton received her doctoral training at the University of Washington and the Fred Hutchinson Cancer Research Center in Seattle, Washington, and her master's training at Harvard University. Before her training in epidemiology, she was an environmental health scientist, consulting to industry and government on health risk assessment. She also served as a high school science and math teacher through the Peace Corps in Swaziland, Africa. Dr. Herrinton directs a program in inflammatory bowel disease that is focused on epidemiology, quality of care, and outcomes. She also serves as site principal investigator on several research consortia organized under the HMO Research Network, including the Centers for Education and Research in Therapeutics. She leads and participates in numerous collaborative projects concerned primarily with health care effectiveness, as well as patient-reported quality of life. She has conducted training in collaboration, and has mentored doctoral students, physicians, and newer investigators in research and career development. Her studies have involved data collection through linkage, medical record review, patient survey, provider survey, and qualitative approaches such as guided interviewing and focus groups. Besides her work, Dr. Herrinton also enjoys her family and friends, hiking, biking, and swimming.

Current Position(s):

Research Scientist III, Division of Research, Kaiser Permanente Northern California
Associate Editor, American Journal of Epidemiology

Primary Research Interests:

Inflammatory bowel disease
Cancer
Etiology factors
Quality of care outcomes
Epidemiology methods
Outcomes research

Related Web sites

Autoimmune Disease Registry

Safety Assessment of Anti-TNF Agents Used in Autoimmune Disease

This study will identify the risk of developing serious adverse events (e.g., infections and cancer), while using biologic therapies for the treatment of inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.
Funder: Agency for Healthcare Research and Quality
Principal Investigator: Herrinton, Lisa

Kaiser Permanente Autoimmune Disease Registry

This study establishes the Kaiser Permanente Autoimmune Disease Registry, containing comprehensive clinical information for a large, diverse population with access to DNA for future genotyping and functional assays.
Funder: Nat. Inst. of Allergy and Infectious Diseases
Principal Investigator: Herrinton, Lisa

Data Mining Electronic Health Records for Drug Adverse Events

When a new pharmaceutical drug enters the market, there are always questions about its effectiveness and safety profile in comparison with other related drugs; this project will use two data mining methods (the tree-based scan statistic and Bayesian gamma Poisson shrinkage) to search for unexpected drug adverse events.
Funder: Agency for Healthcare Research and Quality
Principal Investigator: Herrinton, Lisa

Prenatal and Early Life Predictors of Pediatric Onset Inflammatory Bowel Disease

The goal of this study is to identify prenatal and early life exposures that predict development of pediatric onset inflammatory bowel disease (IBD); identifying modifiable, early life risk factors is imperative for developing interventions to prevent IBD in susceptible individuals.
Funder: Health Resources and Services Administration
Principal Investigator: Herrinton, Lisa

Patterns of Use of Biologic Drugs in Immune-mediated Disease

This study assesses whether elders have adequate and appropriate access to biologic agents for the treatment of their rheumatoid arthritis, and illuminates the reasons for under-use and suboptimal selection of these agents.
Funder: Genentech
Principal Investigator: Herrinton, Lisa

Epidemiology of Hepatosplenic T-Cell Lymphoma

This study examines the incidence rate of Hepatosplenic T-cell lymphoma (HSTCL) among Kaiser Permanente Northern California crohn's disease patients who have used the biologic medication infliximab.
Funder: Centocor
Principal Investigator: Herrinton, Lisa

HMORN Centers for Education and Research Therapeutics (CERT3): Infrastructure

This funding allows for the creation and maintenance of an infrastructure to support research and education on therapeutics among nine participating members of the HMO Research Network. The projects conducted to date range from drug safety assessments to the impact of drug copayments on patients with diabetes.
Funder: Agency for Healthcare Research and Quality
Principal Investigator: Herrinton, Lisa

Practice Variation in Management of Inflammatory Bowel Disease

The study describes the natural history of CD and UC, and whether care is consistent with practice guidelines. It will assess predictors of therapies, visits, and procedures, including predictors at the level of the patient, the disease, the provider, and the clinic.
Funder: Centers for Disease Control and Prevention
Principal Investigator: Herrinton, Lisa

Is Stroke a Late Effect of Chemotherapy?

This study will use the patient and Virtual Data Warehouse resources of the Cancer Research Network to estimate incidence of stroke by treatment modality among patients diagnosed from 1994 to 2003 with bladder, female breast, colorectal, Hodgkin's lymphoma, adult leukemia multiple myeloma, non-Hodgkin's lymphoma, ovarian and testicular cancers.
Funder: National Institute of Aging
Principal Investigator: Herrinton, Lisa

5-ASA Use and Risk of Colorectal Dysplasia and Cancer Among Ulcerative Colitis Patients

This study assesses the effectiveness of 5-aminosalicylic acid (5-ASA) as a potential chemopreventive agent against colorectal dysplasia and cancer in patients with ulcerative colitis.
Funder: Proctor and Gamble
Principal Investigator: Herrinton, Lisa

HR-QOL in Colorectal Cancer Survivors with Stomas

This case control study assesses ES Health Related Quality of Life (HR-QOL) among Colorectal Cancer survivors (=> 5 yrs) with and without stomas.
Funder: National Cancer Institute
Principal Investigator: Herrinton, Lisa

Kaiser Permanente Division of Research